Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665154 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04665154 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT04665154, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG MAS825
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04665154
The ClinicalTrials.gov registry entry for NCT04665154 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04665154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04665154 about?
NCT04665154 is a clinical study titled "A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers". The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.
What is the current status of trial NCT04665154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2019-06-07. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT04665154?
The interventions under investigation include: Placebo (DRUG), MAS825 (DRUG).
Who is sponsoring clinical trial NCT04665154?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.